Written question asked by Andrew Gwynne (Labour) on Wednesday, 13 July 2022, in the House of Commons. It was due for an answer on Monday, 18 July 2022 (named day). A holding answer was provided on Monday, 18 July 2022. A substantive answer was provided by Maggie Throup (Conservative) on Tuesday, 19 July 2022 on behalf of the Department of Health and Social Care.
Tixagevimab/cilgavimab
- Question
-
To ask the Secretary of State for Health and Social Care, if he will take steps to ensure that the continued consultations around the rollout of Evusheld do not impede his Department’s ability to procure that antiviral drug.
- Answer
-
The Department is conducting an assessment of Evusheld, including requesting advice from clinicians on the most appropriate option for the National Health Service in line with available data, the public health situation and other treatments available. While we are considering the advice received, we are currently unable to confirm a specific timetable for any decision.
In addition, the Department is determining the most appropriate patient groups which could potentially benefit from prophylactic treatment and any considerations on potential deployment.
Secondary information
- Type
- Written question
- Reference
- 35896
- Session
- 2022-23
- Subjects
- Procurement Tixagevimab/cilgavimab
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2024-05-24 10:02:42 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/35896
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/35896
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/commons/2022-23/35896